Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. Chow RD, Mamtani R. Urol Oncol 2025;43:597.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chow RD, Mamtani R. Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. Urol Oncol 2025;43:597.
PMID: 40753014